ArticleFrontiers in nutrition2025
Association between neutrophil percentage to albumin ratio and sarcopenia among cancer patients: evidence from both the Chinese and American cohorts.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sarcopenia, the progressive depletion of skeletal muscle mass and strength, worsens quality of life, and survival in cancer patients. Given its multifactorial pathogenesis involving chronic inflammation and malnutrition, integrated biomarkers for early risk assessment are needed. Methods: This two-cohort study investigated the clinical utility of the neutrophil percentage-to-albumin ratio (NPAR) for sarcopenia risk stratification. We analyzed data from the US National Health and Nutrition Examination Survey (NHANES, Results: Elevated NPAR was significantly associated with higher odds of sarcopenia in both the American (OR = 1.14, 95% CI: 1.06-1.22) and Chinese (OR = 1.10, 95% CI: 1.04-1.14) populations, showing a dose-response relationship. Non-linear threshold effects were identified at NPAR = 14.7 (NHANES) and NPAR = 17.07 (Chinese cohort). NPAR outperformed other inflammatory indices in the clinical cohort (AUC = 0.568). Systemic inflammation (C-reactive protein) and dietary protein intake mediated 17.10% and 6.37% of the association, respectively. Sensitivity analyses supported robustness. Conclusions: NPAR is a practical and cost-effective inflammatory-nutritional biomarker for sarcopenia risk stratification in cancer patients. It shows promise for early identification and personalized intervention across diverse populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.